Given the cardioprotective and renoprotective effects of SGLT2 inhibitors, should we consider administering to patients with well controlled type 1 diabetes despite the risk of DKA?  

The key word in this question is "consider". GIven the lack of published clinical trials to assess efficacy (CV and CKD hard outcomes) versus safety (DKA) in this population, an answer at this time would be a qualified yes, with the qualifications being a well-motivated patient who adheres to self-g...

It has been approved for use in Europe for type I DM.

No! If well-controlled, the draining off of glucose leads to usage of fatty acids for energy and increased risk of DKA, especially in Type 1 diabetes  patients.